Tokyo, Oct. 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000057593) titled 'Novel Fecal Biomarker for Irritable Bowel Syndrome' on Oct. 1.
Study Type:
Observational
Primary Sponsor:
Institute - Tohoku University
Condition:
Condition - Patients with Irritable Bowel Syndrome and Healthy Subjects
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - Comparing the composition of membrane vesicles between patients with irritable bowel syndrome and healthy subjects
Basic objectives2 - Others
Eligibility:
Age-lower limit - 18
years-old
=
Gender - Male and Female
Key inclusion criteria - IBS patients: meet Rome IV criteria for IBS and do not meet the exclusion criteria
Healthy subjects: those who do not meet Rome IV criteria and have no other complications
Key exclusion criteria - IBS patients: have histories of abdominal surgeries and/or colorectal diseases other than IBS
Healthy controls: have other serious complications
Target Size - 100
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2025 Year 04 Month 08 Day
Anticipated trial start date - 2025 Year 10 Month 01 Day
Last follow-up date - 2027 Year 09 Month 30 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000065800
Disclaimer: Curated by HT Syndication.
